Trial Profile
Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms VENICE
- 18 Jul 2010 Results have been presented at the 18th International AIDS Conference.
- 10 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.